Edition:
United States

AmerisourceBergen Corp (ABC.N)

ABC.N on New York Stock Exchange

84.77USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$84.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
424,280
52-wk High
$106.26
52-wk Low
$71.90

Latest Key Developments (Source: Significant Developments)

Amerisourcebergen Production At Pharmedium's Memphis Outsourcing Facility Remains Voluntarily Suspended
Monday, 2 Apr 2018 07:39am EDT 

April 2 (Reuters) - AmerisourceBergen Corp ::PRODUCTION AT PHARMEDIUM'S MEMPHIS OUTSOURCING FACILITY REMAINS VOLUNTARILY SUSPENDED.COMPLETING CERTAIN REMEDIATION MEASURES AT PHARMEDIUM'S MEMPHIS OUTSOURCING FACILITY.SEC FILING.WORKING TO RESUME PRODUCTION AT MEMPHIS FACILITY.  Full Article

Deal talks between Walgreens and AmerisourceBergen have ended without an agreement- CNBC‍​
Tuesday, 27 Feb 2018 11:52am EST 

Feb 27 (Reuters) - :TALKS BETWEEN WALGREENS AND AMERISOURCEBERGEN ABOUT AN ACQUISITION OF THE WHOLESALE DRUG DISTRIBUTOR HAVE ENDED WITHOUT AN AGREEMENT - CNBC, CITING SOURCES‍​.  Full Article

Walgreens In Early-Stage Talks To Buy AmerisourceBergen- CNBC,Citing DJ
Monday, 12 Feb 2018 05:36pm EST 

Feb 12 (Reuters) - :WALGREENS IN EARLY-STAGE TALKS TO BUY AMERISOURCEBERGEN, OF WHICH IT ALREADY OWNS 26 PERCENT - CNBC,CITING DJ.  Full Article

Amerisourcebergen Reports Fiscal 2018 First Quarter Results
Tuesday, 6 Feb 2018 06:30am EST 

Feb 6 (Reuters) - Amerisourcebergen Corp ::AMERISOURCEBERGEN REPORTS FISCAL 2018 FIRST QUARTER RESULTS.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $6.45 TO $6.65.Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.55 EXCLUDING ITEMS.Q1 GAAP EARNINGS PER SHARE $3.90.REVENUES OF $40.5 BILLION FOR Q1, A 6.0 PERCENT INCREASE YEAR-OVER-YEAR.AMERISOURCEBERGEN - ADJUSTED EARNINGS PER SHARE BENEFIT FROM U.S. TAX REFORM IS EXPECTED TO BE ABOUT $0.60 IN FISCAL 2018.SEES 2018 ‍ADJUSTED DILUTED EARNINGS PER SHARE TO BE IN RANGE OF $6.45 TO $6.65​.SEES 2018 ‍REVENUE GROWTH IN RANGE OF 8 PERCENT TO 11 PERCENT​.AMERISOURCEBERGEN - "REMAIN CONFIDENT IN PHARMEDIUM'S ABILITY TO RETURN TO ITS LONG-TERM GROWTH TRAJECTORY".SEES 2018 ‍CAPITAL EXPENDITURES OF APPROXIMATELY $325 MILLION​.Q1 EARNINGS PER SHARE VIEW $1.35, REVENUE VIEW $40.50 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $6.29, REVENUE VIEW $166.80 BILLION -- THOMSON REUTERS I/B/E/S.AMERISOURCEBERGEN - CONTINUES TO OPERATE UNDER ASSUMPTION THAT BRAND DRUG INFLATION WILL BE IN RANGE OF 6 PERCENT TO 7 PERCENT FOR PHARMACEUTICAL MARKET IN 2018.AMERISOURCEBERGEN - CONTINUES TO OPERATE UNDER ASSUMPTION THAT GENERIC DRUG DEFLATION WILL BE IN RANGE OF -7 PERCENT TO -9 PERCENT FOR PHARMACEUTICAL MARKET IN 2018.  Full Article

AmerisourceBergen Announces Operating Commitments to Address Opioid Diversion And Abuse
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - Amerisourcebergen Corp ::AMERISOURCEBERGEN ANNOUNCES OPERATING COMMITMENTS TO ADDRESS OPIOID DIVERSION AND ABUSE.AMERISOURCEBERGEN - WILL CONTINUE TO REPORT QUANTITY, RECEIVING PHARMACY OF ALL ORDERS OF OPIOID-BASED MEDICINES TO DRUG ENFORCEMENT AGENCY ON DAILY BASIS.  Full Article

AmerisourceBergen Prices $750 Mln 3.45 Pct Senior Notes Due 2027
Wednesday, 29 Nov 2017 05:16pm EST 

Nov 29 (Reuters) - AmerisourceBergen Corp ::AMERISOURCEBERGEN PRICES $750 MILLION 3.45% SENIOR NOTES DUE 2027 AND $500 MILLION 4.30% SENIOR NOTES DUE 2047.  Full Article

AmerisourceBergen to acquire H. D. Smith
Monday, 20 Nov 2017 04:52pm EST 

Nov 20 (Reuters) - AmerisourceBergen Corp ::AmerisourceBergen to acquire H. D. Smith.AmerisourceBergen Corp - deal for ‍$815 million in cash​.AmerisourceBergen Corp - ‍plans to fund acquisition through issuance of new long-term debt​.AmerisourceBergen Corp - ‍acquisition is expected to be slightly accretive to adjusted diluted EPS in fiscal year 2018​.AmerisourceBergen Corp - ‍acquisition expected to achieve full run-rate synergies, be about $0.15 accretive to adjusted EPS in FY 2020​.AmerisourceBergen Corp - ‍company now expects fiscal year 2018 adjusted operating income growth to be in range of 4 percent to 7 percent​.AmerisourceBergen Corp - now sees revenue growth to be in range of 8 percent to 11 percent​ for fiscal year 2018.AmerisourceBergen Corp - ‍reaffirming rest of previously announced fiscal 2018 financial guidance​.AmerisourceBergen - expects fiscal year 2018 pharmaceutical distribution services segment operating income growth in range of 4 percent to 7 percent​.  Full Article

AmerisourceBergen increases dividend 4 percent
Thursday, 9 Nov 2017 09:00am EST 

Nov 9 (Reuters) - Amerisourcebergen Corp ::Increases dividend 4 percent.Increased company's quarterly dividend rate 4 percent to $0.38 per common share from $0.365 per common share​​.  Full Article

AmerisourceBergen, on conf call, says current trends indicate that generic buy side deflation rate has not worsened
Thursday, 2 Nov 2017 12:23pm EDT 

Nov 2 (Reuters) - AmerisourceBergen Corp ::AmerisourceBergen CEO, on conf call, says an aging U.S. patient population continues to "demand" the support of pharmaceutical intervention​.AmerisourceBergen CFO, on conf call - continue to experience headwind from lower Hepatitis C revenues this quarter, consistent with overall U.S. market trends.AmerisourceBergen CFO, on conf call - continue to see strong volume, revenue growth for oncology drugs due to expanded indications of overall market growth.AmerisourceBergen CFO, on conf call says our PharMEDium business experienced an increase in sequential shipping volumes in Q4.AmerisourceBergen CFO, on conf call, says current trends indicate that the generic buy side deflation rate has not worsened.AmerisourceBergen CFO, on conf call, says it is likely that only Q4 will have a full benefit of new pharmacies from Walgreens-Rite Aid deal.AmerisourceBergen CFO, on conf call, says transitioning customer contracts to more "balanced pricing" to offset lower contributions from generics.AmerisourceBergen, on conf call, when asked about Amazon's entry into drug supply chain, says "we haven't really counted Amazon at all yet as a threat".  Full Article

NY A.G. Schneiderman, coalition of AGs expand investigation into opioid crisis
Tuesday, 19 Sep 2017 12:39pm EDT 

Sept 19 (Reuters) - New York A.G. Schneiderman::New York A.G. Schneiderman, bipartisan coalition of AGs expand multistate investigation into opioid crisis.Says served subpoenas to Endo International, Janssen Pharmaceuticals, Teva Pharmaceutical/Cephalon Inc and Allergan.Says Attorneys General have also served a supplemental investigative subpoena on Purdue Pharma.Attorneys General demanded information about distribution practices from AmerisourceBergen, Cardinal Health, McKesson.  Full Article

AmerisourceBergen sees Memphis plant back on track by 2019; shares rise

Drug distributor AmerisourceBergen Corp posted a better-than-expected quarterly profit on Wednesday and said it expects its Memphis facility to be fully operational by fiscal 2019, sending its shares up 5 percent.